Hemostemix Issues Letter to Shareholders Urging Them to Vote Their WHITE Proxy - Seite 2

Our vision is to build a leading world-class biotech company. The Dissidents' agenda is dangerous - they want to scale back clinical trials and move our business to jurisdictions with poor regulatory oversight. We cannot allow these unknown and inexperienced opportunists to attack your company and destroy its future.

VOTE THE WHITE PROXY TO SUPPORT YOUR COMPANY'S TRUSTED BOARD AND ENSURE THAT THE PROGRESS WE HAVE ACHIEVED IN BRINGING OUR LANDMARK TECHNOLOGY TO MARKET IS NOT LOST!

EXPERIENCED BOARD WITH A PROVEN PLAN TO CREATE VALUE

Our strengthened Board includes extensive biotechnology, pharma, capital markets and legal expertise. Our Life Science Board Members each have unprecedented relevant experience in the healthcare sector; have been involved in the treatment of over 1,000 patients with cell therapies and have a proven track record of success.

Our performance has consistently kept pace with our peers while building a strong foundation for future growth. We have now reached the tipping point of our development process to create even more value for all shareholders. To unlock that value, your management team is leading a number of successful clinical trials. Led by our CEO, Dr. Elmar Burchardt, and members of our Board, we have already achieved significant milestones:

• Critical Regulatory Approvals. Our success in Canada, South Africa and our FDA approval to commence clinical trials in the United States is the direct result of our management team's experience and the significant amount of groundwork already completed.
• Implementation of Phase 2 Clinical Trials. Hemostemix has received clearance to initiate our Phase 2 clinical trial with several leading US institutions.
• More Clinical Trial Sites. The number of trial sites was increased from one to six.
• More Efficiency. We have implemented over 3,000 changes to the original protocol and reduced the number of required subjects from over 200 to 95, while substantially increasing the statistical power of the clinical trial. The changes implemented have dramatically increased the speed at which we can enroll patients.
• Data Analytics. We are already halfway to our interim analysis stage, which will deliver clinical efficacy data. Once the interim analysis is complete, Hemostemix will be in the driver's seat - with an ability to access capital and partner with major pharmaceutical and biotech companies
• Achieved Industry Low Operating Cost. Hemostemix is already operating with the lowest budget of any cell therapy company that is conducting international Phase 2 clinical studies, and we have plans to further reduce our operating costs with low cost/high volume centres. We are currently in late stage discussions to open up clinical trial activities in former Eastern Bloc countries with large numbers of eligible patients that could further reduce our operating costs.

We are on the path to success and in the process of securing the additional financing to advance these trials and monetize our technology. To date, management and key shareholders have invested over $1.2MM of their own capital in non-interest bearing loans to ensure success.